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Abstract
Determining the most promising single-nucleotide polymorphisms (SNPs) presents a challenge in
genome-wide association studies, when hundreds of thousands of association tests are conducted.
The power to detect genetic effects is dependent on minor allele frequency (MAF), and genome-
wide association studies SNP arrays include SNPs with a wide distribution of MAFs. Therefore, it is
critical to understand MAF’s effect on the false positive rate.
Data from the Framingham Heart Study simulated data (Problem 3, with answers) was used to
examine the effects of varying MAFs on the likelihood of false positives. Replication set 1 was used
to generate 1 million permutations of case/control status in unrelated individuals. Logistic
r e g r e s s i o nw a su s e dt ot e s tf o rt h ea s s o c i a t i o nb e t w e e ne a c hS N Pa n dm y o c a r d i a li n f a r c t i o nu s i n g
an additive model. We report the number of “significant” tests by MAF at a =1 0
-4,1 0
-5, and 10
-6.
Common SNPs exhibited fewer false positives than expected. At a =1 0
-4, SNPs with MAF 25% and
50% resulted in 69.2 [95%CI: 62.8-75.6] and 70.8 [95%CI: 61.3-80.4] false positives, respectively,
compared to 100 expected. Rare SNPs exhibited more variability but did not show more false-
positive results than expected by chance. However, at a =1 0
-4, MAF = 5% exhibited significantly
more false positives (105.5 [95%CI: 81-130.1]) than MAF = 25% and 50%. Similar results were seen
at the other alpha values.
These results suggest that removal of low MAF SNPs from analysis due to concerns about inflated
false-positive results may not be appropriate.
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Correct identification of the most promising single-
nucleotide polymorphisms (SNPs) for follow-up is one
of the greatest challenges of conducting genome-wide
association studies (GWAS). Hundreds of thousands of
simultaneous association tests are typically conducted
across the genome, and the resulting p-values or test
statistics are compared and often ranked to determine the
most promising SNPs. This procedure is conducted
regardless of the specific adjustment chosen for multiple
testing correction. For example, the conservative Bonfer-
roni correction toadjust the critical significance threshold
simply lowers the threshold of a to account for the
number of tests conducted; any SNP with a p-value below
that adjusted threshold will be considered significant.
False-discovery rate (FDR) procedures explicitly rank
p-values before selecting the SNPs below the FDR thresh-
old for further consideration. Genome-wide permutation
testing methods involve randomly permuting case and
control status and examining the distribution of the best
resulting test statistic, thus creating an empirical distribu-
tion of extreme test statistics against which to compare
observed results. With each of these methods however, if
multiple SNPs reach this threshold, the investigator must
choose which SNPs to follow for replication.
GWAS SNP arrays necessarily include SNPs with a wide
distribution of minor allele frequencies (MAFs), from
nearly monomorphic (MAF <0.5%) to very common
(MAF≈50%). All of the methods for determining SNP
selection implicitly assume that the p-values or test
statistics from individual SNPs are drawn from the same
distribution, regardless of MAF. If this were true, then
ranking the test statistics from SNPs of different MAF
would be valid. However, the power to detect a given
genetic effect with a given study size depends to a great
extent on the MAF of the risk allele tested. Specifically,
loci with a low MAF (<10%) have significantly lower
power to detect weak genotypic risk ratios than loci with
a high MAF (>40%) [1]. Further, previous studies have
demonstrated that rare genotypes are more likely to
result in spurious findings [2]. Thus, many GWAS have
removed SNPs with MAF<10% [3,4].
It is therefore critical to understand the true effect of MAF
on the likelihood of obtaining a false-positive result (e.g.,
very low p-value) under the null hypothesis of no true
association. We hypothesize that MAF affects the like-
lihood of a specific variant achieving significance thresh-
olds under the null hypothesis. If MAF does affect the
probabilityofachievingaspecificsignificance,thiswould
result in non-comparability of p-values (or test statistics)
between SNPs with different MAFs. To address this issue
we utilized the Genetic Analysis Workshop 16 simulated
data set and performed extensive permutations.
Methods
The Framingham Heart Study simulated data set
(Problem 3, replication 1, with answers) was used in
this analysis. Founders and singletons from the original
pedigree file (N = 849) were selected for this case-control
analysis, using myocardial infarction (event 1) as the
disease status, resulting in 133 cases and 716 controls.
SNPs were eligible for selection if they were located in
genomic regions not associated with myocardial infarc-
tion (null SNPs), of which 50 were selected by MAF and
percent missing data. Ten SNPs, each at lower MAFs of
1% and 5%, and five SNPs, each at MAFs of 10%, 25%,
and 50%, with similar low rates of missing data
(approximately 0%) were selected. To examine effects
of missing data, ten additional SNPs at MAF 5% and five
additional SNPs each at MAF 50% with approximately
5% missing data were also analyzed (Table 1).
One million permutations were conducted per SNP, in
which case or control status was randomly assigned to
an individual in the dataset, keeping the total numbers
of cases and controls consistent. For each permutation,
logistic regression was used to test for the association
between each SNP and myocardial infarction event
1 using an additive model. To determine whether the
test statistic distribution differs by allele frequency we
report the number of false positive “significant” tests by
MAF at a =1 0
-4,1 0
-5,o r1 0
-6. These threshold alpha
values were selected because we could expect at least
one false positive by chance using one million
permutations. Statistical analysis was conducted using
SAS version 9.1.3 (SAS Institute, Cary, NC) on a
dedicated server.
Results
Common SNPs (MAF>25%) exhibited significantly
fewer false positives than expected by chance at all
thresholds tested (e.g., 10
-4,1 0
-5,a n d1 0
-6;F i g u r e1 ) .
Rare SNPs exhibited more variability in the number of
false positives than common SNPs, but did not have
significantly more of false-positive results than expected
by chance. Interestingly, when SNPs with 5% missing
data were analyzed, the findings did not differ from the
results using SNPs with almost no missing data (data not
shown). Given the marked variability in the 1% MAF, the
relationship between numbers of individuals homozy-
gous for the 1% allele and number of false positives was
examined, but no trend was present.
While low MAF SNPs (1% or 5%) did not have elevated
false positives compared to chance, the 5% MAF SNPs
had significantly more false positives than the more
common (25 and 50%) MAF SNPs at the 10
-4 (p <0 . 0 3 )
and 10
-5 (p < 0.05) thresholds. These differences were
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only by examining values at the tail end of the
distribution.
Discussion
The current study provides evidence that false-positive
rate is influenced by MAF. We report that common SNPs
(MAF 25-50%) result in significantly fewer false positives
than expected under the null c
2 distribution, suggesting
that for common SNPs the current thresholds may be too
conservative. Also, we report more false positives with
5% MAF SNPs than with common SNPs at the thresh-
olds examined. In addition, under the null hypothesis,
up to 5% randomly missing data did not impact our
findings. Thus, under the null hypothesis, MAF but not
proportion of missing data appears to affect the like-
lihood of a false positive result.
These results have implications for a common analytical
approach applied to large-scale SNP data. GWAS
analysis often begins by discarding all genotypes for
SNPs of low MAF, typically for those with MAF<10%
[3,4]. This practice results in a huge loss of data. For
example, 35.5% of SNPs on the Affymetrix chips have
MAFs below 10%. In addition, discarding low MAF SNPs
may hamper our ability to detect rare disease-causing
polymorphisms [5].
The reasons for discarding these SNPs may be related to
genotyping issues, such as lower genotyping rates or
concerns about calling accuracy. However, discarding
low-MAF SNPs may also be due to perceptions about the
statistical inferences that result from analyzing such
SNPs. Anecdotally, investigators have expressed “dis-
trust” of significant results arising from low-MAF SNPs.
However, a recent study demonstrated that in the
absence of bias in genotype error rates between cases
and controls, even very small MAFs show type I error
rates close to nominal levels [6]. Our study confirms and
extends this report, showing that nominally significant
results occur significantly less often than expected, even
for low MAF SNPs, resulting in a conservative bias. Thus,
our findings do not support the removal of low MAF
SNPs from analysis due to concerns about inflated false-
positive results.
However, our study does raise the concern about ranking
p-values generated from SNPs across vastly different
MAF. Given our findings, we suggest that the c
2
threshold to establish a particular level of significance
may need to be modified using empirical permutations
for several MAF “bins.” For example, in our analysis
dataset, for an MAF of 25% and a significance threshold
of 10
-5,t h et h r e s h o l dc
2 value would need to be reduced
from 19.51 (from the standard c
2 distribution) to 18.79
to capture the expected 10 false positives. However, it
should be noted that to determine robust estimates, c
2
adjustments, and false positive rates for a GWAS
significance of 10
-8, over 10 billion permutations and
significant computing capability would be required.
Additional studies using larger datasets will be required
to fully understand this issue.
Table 1: SNP Selection
MAF 1% MAF 5% MAF 10% MAF 25% MAF 50%
SNP % Missing SNP % Missing SNP % Missing SNP % Missing SNP % Missing
rs1722601 0 rs6000509 0.06 rs7291198 0.04 rs2413030 0.01 rs165862 0
rs16991890 0.10 rs7289964 0.45 rs2227235 0.10 rs1139793 0.16 rs695670 0.01
rs6001118 0.28 rs9622750 0.16 rs17299838 0.28 rs2071436 0.12 rs5998941 0
rs12157495 0.09 rs6518774 0.12 rs730483 0.04 rs5752905 0.06 rs5758972 0.01
rs16994023 0 rs8139704 0.18 rs9615812 0.03 rs5753917 0.07 rs738536 0
rs5993835 0 rs134049 0 rs2267296 5.67
rs16997431 0.01 rs13058493 0 rs136575 5.29
rs17004911 0 rs16989600 0 rs2254907 4.73
rs7289701 0 rs5998473 0 rs2179321 5.45
rs11912108 0 rs2267613 0 rs6120328 5.65
rs1110477 4.50
rs1476053 4.60
rs16998312 4.75
rs17808497 4.76
rs17762006 5.29
rs6082126 5.27
rs11698699 5.33
rs8120594 4.98
rs16989639 5.33
rs6123569 5.30
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